



BIOMATRIX
THE ALUMINAL BIODEGRADABLE POLYMER DES *FLEX*™

**LESS
RISK**

MORE CONFIDENCE*

LEADERS

4-YEAR RESULTS



BIOSENSORS
INTERNATIONAL™

LESS
RISK

BIOMATRIX
THE ABLUMINAL BIODEGRADABLE POLYMER DES **FLEX**™

MORE
CONFIDENCE!*



LEADERS

4-YEAR RESULTS

Read about the power of BA9™/PLA



“Our findings show that, compared with durable polymer SES, biodegradable polymer BES are non-inferior and can improve long-term clinical outcomes for up to 4 years. Our findings also show that they are associated with an 80% RR reduction compared with durable polymer SES in terms of very late definite ST occurring more than 1 year after stent implantation, with no difference in the risk of ST during the first year. The apparent benefit of biodegradable polymer BES was mainly attributable to a lower risk of primary endpoint events associated with very late definite ST.”¹



Details on-line

[http://www.thelancet.com/journals/laninf/article/PIIS0140-6736\(11\)61672-3/fulltext](http://www.thelancet.com/journals/laninf/article/PIIS0140-6736(11)61672-3/fulltext)




© Copyright Elsevier 2011

1

BioMatrix Flex™ - cutting the MACE rate out to 4 years


MACE defined as cardiac death, MI, clinically indicated TVR



2

80% relative risk reduction in definite VLST with BioMatrix Flex™


VLST=Very late stent thrombosis



3

Reduction in definite VLST associated with fewer cardiac events

VLST=Very late stent thrombosis



See presentation on-line²

http://www.biosensors.com/intl/sites/default/files/eblast/LEADERS_4-year_Results.pdf

All P values are for superiority
 SES - Sirolimus-eluting stents
 BES - Biolimus-eluting stents

* Based on LEADERS results on MACE, definite VLST and cardiac events associated with definite stent thrombosis out to 4 years.

1. Stefanini GG et al., Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4-year follow-up of a randomised non-inferiority trial. **The Lancet**. 2011; 378(9807): 1940-8.
 2. Ischinger T et al., Long-term clinical results from the all-comers LEADERS Trial: 4-year follow-up data, oral abstract presentation, **TCT 2011**.
- © The article was published in The Lancet, Vol 378: Stefanini GG et al., Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4-year follow-up of a randomised non-inferiority trial, Pages 1940-1948. Copyright Elsevier 2011.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

BioMatrix Flex, Biolimus A9 and BA9 are trademarks or registered trademarks of Biosensors International Group, Ltd.

All cited trademarks are the property of their respective owners.

Not available for sale in the United States and certain other countries.

© 2012 Biosensors International Group, Ltd. All rights reserved.